PARP Inhibitor Biomarker Market Size, Trends & Industry 2031
PARP Inhibitor Biomarker Market Size, Trends & Industry 2031
Segments - PARP Inhibitor Biomarker Market by Services (BRCA 1 & 2 Testing, HRD testing, HRR testing, and Others), Product Type (Assays and Kits), Application (Ovarian Cancer, Breast Cancer, and Others), End-user (Clinics, Hospitals, and Others), and Region (Asia Pacific, North America, Latin America, Europe, and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2023 – 2031
Upcoming
| Report ID :HC-5072
| 4.9 Rating
| 60 Reviews
| 198 Pages
| Format :
Report Description
The global PARP inhibitor biomarker market size was USD 726.26 Million in 2022 and is likely to reach USD 5.3 Billion by 2031, expanding at a CAGR of 24.9% during 2023–2031. The growth of the market is due to the rising prevalence of chronic diseases such as cancer and the subsequent need for effective diagnosis and treatment.
Genomic integrity of the human cells helps the human mechanism to perform all its physiological and immunological functions optimally. When genomic integrity is affected due to genomic instability some life-threatening changes occur in the human body affecting immunological functions significantly. When the genomic integrity of a human cell reaches beyond its peak level it causes cancer initiation and progression. The cancer cells survive and multiply with the help of proteins such as Poly(ADP-ribose) polymerase (PARP).
Poly(ADP-ribose) polymerase (PARP) is a type of protein that aids cancer cells to repair themselves. It is responsible for essential cellular functions such as maintaining genomic integrity, DNA repair, and programmed cell death. DNA repair is a set of processes adopted by human cells to identify and regulate damage to the DNA molecules while keeping the genome integrity and genome stability intact. Poly(ADP-ribose) polymerase (PARP) inhibitor is a type of drug therapy that works by preventing enzymes involved in DNA repair processes thereby limiting the growth of cancer cells.
Genomic abnormalities are caused by disruptions in the DNA repair mechanism in the human body that maintains a balance between genomic integrity and cell survival. Poly(adenosine diphosphate-ribose) polymerase 1 (PARP1) inhibitor biomarkers is a clinically approved diagnostics and drug therapy designed to accelerate DNA repair to treat a variety of cancers with defective DNA repair pathways. PARP inhibitors are used to block enzymes called poly ADP ribose polymerase (PARP) in human cells and recover damaged DNA. PARP inhibitor biomarkers are a type of Cancer biomarkers used to identify, assess, and evaluate cancerous processes in the human mechanism.
PARP Inhibitor Biomarker Market Dynamics
Drivers
Increasing prevalence of a variety of cancers globally is anticipated to drive the market. PARP inhibitors serve as an effective mode of diagnosing and treating breast and ovarian cancers. According to the World Health Organization (WHO), cancer accounted for nearly 10 Million deaths in 2020.
Restraints
Stringent government regulatory framework for approval of biomarkers and high cost are likely to hinder the market. Cancer is a life-threatening disease with a diverse set of complexities and complications. Regulators ascertain if the novel treatments are target-specific and safe before approving the drug therapies. The cost of drug therapies increases as a result of multiple complex research operations to increase the efficacy and safety of the biomarkers.
Opportunities
Developments in PARP inhibitor biomarkers with enhanced clinical activity and optimal target engagement is likely to create multiple opportunities in the market. The efficacy of PARP inhibitors biomarkers increases with highly precise and calibrated targeted novel combinational therapies for diagnostic and therapeutic purposes.
Scope of PARP Inhibitor Biomarker Market Report
The market report includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have been included in the report.
|
Attributes |
Details |
|
Report Title |
PARP Inhibitor Biomarker Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast |
|
Base Year |
2022 |
|
Historic Data |
2016–2021 |
|
Forecast Period |
2023–2031 |
|
Segmentation |
Services (BRCA 1 & 2 Testing, HRD testing, HRR testing, and Others), Product Type (Assays and Kits), Application (Ovarian Cancer, Breast Cancer, and Others), and End-user (Clinics, Hospitals, and Others) |
|
Regional Scope |
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa |
|
Report Coverage |
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, Market Trends, and Revenue Forecast |
|
Key Players Covered in the Report |
Myriad Genetics; Invitae Corporation; NeoGenomics Laboratories; F. Hoffmann-La Roche Ltd; and BPS Bioscience, Inc. |
PARP Inhibitor Biomarker Market Segment Insights
Based on services, the global PARP inhibitor biomarker market is divided into BRCA 1 & 2 Testing, HRD testing, HRR testing, and others. The BRCA 1 & 2 testing segment is expected to expand at a significant growth pace during the projection period owing to the easy administration of biomarkers and accurate diagnosis results. The BCRA gene test is carried out to detect the mutations in the DNA that is responsible for breast cancer. The test is easily carried out by taking samples of blood or saliva.
On the basis of product type, the global market is segregated into assays and kits. The kits segment is projected to register a considerable CAGR during the forecast period due to the convenience offered by the test kits in terms of accessibility and operability of the test instruments. The test kits offer flexibility, portability, and movability.
Based on application, the market is segmented into ovarian cancer, breast cancer, and others. The breast cancer segment is expected to register a robust growth rate during the forecast period owing to the efficacy of PARP inhibitor biomarkers in breast cancer diagnostics. BRCA1 and BRCA2 are inherited-altered genes that increase the risk of breast cancer. Genomic biomarkers and PARP inhibitor biomarkers provide accurate results about the progression of breast cancer.
In terms of region, the global PARP inhibitor biomarker market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is expected to dominate the market during the projection period owing to improved healthcare infrastructure and growing adoption of novel therapies for the diagnosis and treatment of chronic diseases. Rising prevalence of various types of cancers in the subcontinent is boosting the market.
Segments
The global PARP inhibitor biomarker market has been segmented on the basis of
Services
- BRCA 1 & 2 Testing
- HRD testing
- HRR testing
- Others
Product Type
- Assays
- Kits
Application
- Ovarian Cancer
- Breast Cancer
- Others
End-user
- Clinics
- Hospitals
- Others
Region
- Asia Pacific
- North America
- Latin America
- Europe
- Middle East & Africa
Key Players
- Myriad Genetics
- Invitae Corporation
- F. Hoffmann-La Roche Ltd.
- NeoGenomics Laboratories
- BPS Bioscience, Inc.
Competitive Landscape
Players competing in the global PARP inhibitor biomarker market are Myriad Genetics; Invitae Corporation; NeoGenomics Laboratories; F. Hoffmann-La Roche Ltd; and BPS Bioscience, Inc. These companies adopted development strategies including mergers, collaboration, R&D investments, acquisitions, product launches, partnerships, divestitures, and production expansion to increase their consumer base worldwide. For instance,
- In April 2020, GSK announced that the FDA has approved a first-line monotherapy maintenance treatment PARP-inhibitor for women with platinum-responsive advanced ovarian cancer. GSK announced that it has received FDA approval for Zejula(niraparib), a PARP inhibitor that can be consumed once daily as a monotherapy treatment.
Table Of Content
1. Executive Summary2. Assumptions and Acronyms Used
3. Research Methodology
4. PARP Inhibitor Biomarker Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. PARP Inhibitor Biomarker Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. PARP Inhibitor Biomarker Market - Supply Chain
4.5. Global PARP Inhibitor Biomarker Market Forecast
4.5.1. PARP Inhibitor Biomarker Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. PARP Inhibitor Biomarker Market Size (000’ Units) and Y-o-Y Growth
4.5.3. PARP Inhibitor Biomarker Market Absolute $ Opportunity
5. Global PARP Inhibitor Biomarker Market Analysis and Forecast by Applications
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Applications
5.2.2. Y-o-Y Growth Projections by Applications
5.3. PARP Inhibitor Biomarker Market Size and Volume Forecast by Applications
5.3.1. Ovarian Cancer
5.3.2. Breast Cancer
5.3.3. Others
5.4. Absolute $ Opportunity Assessment by Applications
5.5. Market Attractiveness/Growth Potential Analysis by Applications
6. Global PARP Inhibitor Biomarker Market Analysis and Forecast by End Users
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by End Users
6.2.2. Y-o-Y Growth Projections by End Users
6.3. PARP Inhibitor Biomarker Market Size and Volume Forecast by End Users
6.3.1. Clinics
6.3.2. Hospitals
6.3.3. Others
6.4. Absolute $ Opportunity Assessment by End Users
6.5. Market Attractiveness/Growth Potential Analysis by End Users
7. Global PARP Inhibitor Biomarker Market Analysis and Forecast by Region
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Region
7.2.2. Y-o-Y Growth Projections by Region
7.3. PARP Inhibitor Biomarker Market Size and Volume Forecast by Region
7.3.1. North America
7.3.2. Latin America
7.3.3. Europe
7.3.4. Asia Pacific
7.3.5. Middle East and Africa (MEA)
7.4. Absolute $ Opportunity Assessment by Region
7.5. Market Attractiveness/Growth Potential Analysis by Region
7.6. Global PARP Inhibitor Biomarker Demand Share Forecast, 2019-2026
8. North America PARP Inhibitor Biomarker Market Analysis and Forecast
8.1. Introduction
8.1.1. Basis Point Share (BPS) Analysis by Country
8.1.2. Y-o-Y Growth Projections by Country
8.2. North America PARP Inhibitor Biomarker Market Size and Volume Forecast by Country
8.2.1. U.S.
8.2.2. Canada
8.3. Absolute $ Opportunity Assessment by Country
8.4. North America PARP Inhibitor Biomarker Market Size and Volume Forecast by Applications
8.4.1. Ovarian Cancer
8.4.2. Breast Cancer
8.4.3. Others
8.5. Basis Point Share (BPS) Analysis by Applications
8.6. Y-o-Y Growth Projections by Applications
8.7. North America PARP Inhibitor Biomarker Market Size and Volume Forecast by End Users
8.7.1. Clinics
8.7.2. Hospitals
8.7.3. Others
8.8. Basis Point Share (BPS) Analysis by End Users
8.9. Y-o-Y Growth Projections by End Users
8.10. Market Attractiveness/Growth Potential Analysis
8.10.1. By Country
8.10.2. By Product Type
8.10.3. By Application
8.11. North America PARP Inhibitor Biomarker Demand Share Forecast, 2019-2026
9. Latin America PARP Inhibitor Biomarker Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.1.3. Latin America Average Pricing Analysis
9.2. Latin America PARP Inhibitor Biomarker Market Size and Volume Forecast by Country
9.2.1. Brazil
9.2.2. Mexico
9.2.3. Rest of Latin America
9.3. Absolute $ Opportunity Assessment by Country
9.4. Latin America PARP Inhibitor Biomarker Market Size and Volume Forecast by Applications
9.4.1. Ovarian Cancer
9.4.2. Breast Cancer
9.4.3. Others
9.5. Basis Point Share (BPS) Analysis by Applications
9.6. Y-o-Y Growth Projections by Applications
9.7. Latin America PARP Inhibitor Biomarker Market Size and Volume Forecast by End Users
9.7.1. Clinics
9.7.2. Hospitals
9.7.3. Others
9.8. Basis Point Share (BPS) Analysis by End Users
9.9. Y-o-Y Growth Projections by End Users
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.11. Latin America PARP Inhibitor Biomarker Demand Share Forecast, 2019-2026
10. Europe PARP Inhibitor Biomarker Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Europe Average Pricing Analysis
10.2. Europe PARP Inhibitor Biomarker Market Size and Volume Forecast by Country
10.2.1. Germany
10.2.2. France
10.2.3. Italy
10.2.4. U.K.
10.2.5. Spain
10.2.6. Russia
10.2.7. Rest of Europe
10.3. Absolute $ Opportunity Assessment by Country
10.4. Europe PARP Inhibitor Biomarker Market Size and Volume Forecast by Applications
10.4.1. Ovarian Cancer
10.4.2. Breast Cancer
10.4.3. Others
10.5. Basis Point Share (BPS) Analysis by Applications
10.6. Y-o-Y Growth Projections by Applications
10.7. Europe PARP Inhibitor Biomarker Market Size and Volume Forecast by End Users
10.7.1. Clinics
10.7.2. Hospitals
10.7.3. Others
10.8. Basis Point Share (BPS) Analysis by End Users
10.9. Y-o-Y Growth Projections by End Users
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.11. Europe PARP Inhibitor Biomarker Demand Share Forecast, 2019-2026
11. Asia Pacific PARP Inhibitor Biomarker Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Asia Pacific Average Pricing Analysis
11.2. Asia Pacific PARP Inhibitor Biomarker Market Size and Volume Forecast by Country
11.2.1. China
11.2.2. Japan
11.2.3. South Korea
11.2.4. India
11.2.5. Australia
11.2.6. Rest of Asia Pacific (APAC)
11.3. Absolute $ Opportunity Assessment by Country
11.4. Asia Pacific PARP Inhibitor Biomarker Market Size and Volume Forecast by Applications
11.4.1. Ovarian Cancer
11.4.2. Breast Cancer
11.4.3. Others
11.5. Basis Point Share (BPS) Analysis by Applications
11.6. Y-o-Y Growth Projections by Applications
11.7. Asia Pacific PARP Inhibitor Biomarker Market Size and Volume Forecast by End Users
11.7.1. Clinics
11.7.2. Hospitals
11.7.3. Others
11.8. Basis Point Share (BPS) Analysis by End Users
11.9. Y-o-Y Growth Projections by End Users
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.11. Asia Pacific PARP Inhibitor Biomarker Demand Share Forecast, 2019-2026
12. Middle East & Africa PARP Inhibitor Biomarker Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Middle East & Africa Average Pricing Analysis
12.2. Middle East & Africa PARP Inhibitor Biomarker Market Size and Volume Forecast by Country
12.2.1. Saudi Arabia
12.2.2. South Africa
12.2.3. UAE
12.2.4. Rest of Middle East & Africa (MEA)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Middle East & Africa PARP Inhibitor Biomarker Market Size and Volume Forecast by Applications
12.4.1. Ovarian Cancer
12.4.2. Breast Cancer
12.4.3. Others
12.5. Basis Point Share (BPS) Analysis by Applications
12.6. Y-o-Y Growth Projections by Applications
12.7. Middle East & Africa PARP Inhibitor Biomarker Market Size and Volume Forecast by End Users
12.7.1. Clinics
12.7.2. Hospitals
12.7.3. Others
12.8. Basis Point Share (BPS) Analysis by End Users
12.9. Y-o-Y Growth Projections by End Users
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.11. Middle East & Africa PARP Inhibitor Biomarker Demand Share Forecast, 2019-2026
13. Competition Landscape
13.1. Global PARP Inhibitor Biomarker Market: Market Share Analysis
13.2. PARP Inhibitor Biomarker Distributors and Customers
13.3. PARP Inhibitor Biomarker Market: Competitive Dashboard
13.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
13.4.1. Myriad Genetics
13.4.2. Invitae Corporation
13.4.3. NeoGenomics Laboratories
13.4.4. F. Hoffmann-La Roche Ltd.
13.4.5. BPS Bioscience, Inc.
Methodology
Related Reports
Some other reports from this category!
Our Clients
